Columnist Ann Reynoso says she can't get used to the chronic cough of PF, but she's working to overcome the fear and ...
Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their ...
Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Are you familiar with the website Healthgrades? The site allows ...
Brainomix and Boehringer Ingelheim will advance testing of an AI-based analysis tool that may enable earlier diagnosis of PF.
In 2019 Christie Patient relocated to San Francisco to care for her mother, Holly, before and after her double-lung transplant. Holly’s idiopathic pulmonary fibrosis diagnosis came only months before ...
The Phase 3 REBUILD clinical trial, which tested Bellerophon Therapeutics‘ inhaled nitric oxide therapy INOpulse in people with pulmonary fibrosis at risk of developing pulmonary hypertension, failed ...
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).
Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...
Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...
There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results